SE	C Form 4			
	FORM 4	UNITED STATES SECURITIES AND EXCHANGE COMMISSION		
		Washington, D.C. 20549	OMB APPROVAI	
\cup	Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See	STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP	OMB Number: Estimated average bu	3235 urden
	Instruction 1(b).	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934	hours per response:	

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

1. Name and Addre Ferayorni Jus	ess of Reporting Pers stin John	ST	2. Issuer Name and Ticker or Trading Symbol <u>STREAMLINE HEALTH SOLUTIONS</u> <u>INC.</u> [STRM]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director X 10% Owne			
(Last) 5050 AVENIDA	(First) (Middle)			ate of Earliest Trans	action (Month	n/Day/Year)		Officer (give ti below)		her (specify low)	
SUITE 360		4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)						6. Individual or Joint/Group Filing (Check Applicable Line)			
(Street) CARLSBAD	СА							X Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City)	(State)	(Zip)		Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.								
		Table I - N	lon-Derivative	Securities Ac	quire	d, Di	sposed of,	or Be	neficial	y Owned		
Date			2. Transaction Date (Month/Day/Year)	Execution Date,		iction Instr.				5. Amount of Securities Beneficially Owned Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership
					Code	v	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)		(Instr. 4)
Common Stock,	\$0.01 par value									583,633(1)	D	

Common Stock, \$0.01	l par value

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)															
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Transaction(s) (Instr. 4)		
Warrant (right to buy) ⁽⁴⁾	\$0.38	02/07/2024		Α		460,526		02/07/2024	02/07/2028	Common Stock, \$0.01 par value	460,526	\$0.38	460,526	I	Refer to footnote. ⁽⁵⁾

Explanation of Responses:

1. The reported securities represent shares owned directly by Mr. Ferayorni.

2. The reported securities represent 4,244,334 shares held directly by Tamarack Global Healthcare Fund, L.P. ("Fund 1") and 686,548 shares held directly by Tamarack Global Healthcare Fund QP, L.P. ("Fund 2"). Tamarack Capital Management, LLC is the general partner of Fund 1 and Fund 2, Tamarack Advisors, LP is the investment advisor to Fund 1 and Fund 2, and Justin J. Ferayorni is the sole managing member of both Tamarack Capital Management, LLC and Tamarack Capital GP, LLC. Tamarack Capital Management, LLC, Tamarack Advisors, LP, and Mr. Ferayorni may be deemed indirect beneficial owners of the shares held by Fund 1 and Fund 2 for purposes of Section 13(d) of the Securities Exchange Act of 1934 (the "Act").

3. Tamarack Capital Management, LLC, Tamarack Advisors, LP, and Mr. Ferayorni disclaim beneficial ownership of any of the shares held by Fund 1 and Fund 2 for the purpose of determining whether they are subject to Section 16 of the Act, however, in reliance on Rule 16a-1(a)(v) and (vii) under the Act. To the extent that they might be deemed subject to Section 16, they disclaim beneficial ownership of securities held by the Fund 1 and Fund 2 for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein, if any.

4. Reflects a warrant to purchase 460,526 shares of the Issuer's common stock, par value \$0.01 per share, acquired in connection with a private placement offering by the Issuer. The Warrant has an exercise price of \$0.38 per share, is exercisable immediately, and will expire on February 7, 2028.

5. The reported securities are owned directly by The Ferayorni Family Trust for which Mr. Ferayorni serves as trustee.

/s/ Justin J. Ferayorni

02/08/2024 Date

4,930,882

3235-0287

Refer to

footnote.(2)(3)

0.5

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.